Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Creatinine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Creatinine SCHEMBL288087 | 0.98 | CRBN (0.61) | — | |
| Creatinine SCHEMBL8809815 | 0.98 | CRBN (0.61) | — | |
| Creatinine SCHEMBL7203535 | 0.98 | — | — | |
| Creatinine SCHEMBL16295 | 0.98 | — | — | |
| Creatinine SCHEMBL6473476 | 0.95 | — | — | |
| Creatinine SCHEMBL8637084 | 0.95 | — | — | |
| Creatinine SCHEMBL4332495 | 0.95 | — | — | |
| Creatinine SCHEMBL2922002 | 0.95 | — | — | |
| Creatinine SCHEMBL3514057 | 0.95 | — | — | |
| Creatinine SCHEMBL21404081 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798120-A | Preparation method of creatine monohydrate | 安徽泰格生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119798120-A | Preparation method of creatine monohydrate | 安徽泰格生物科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-222267099-U | Be used for creatine monohydrate production synthesizer | 宁夏享誉生物科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-118834137-A | Novel preparation method of sarcosine and derivatives thereof | 潜江永安药业股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118594603-A | Material for reducing impurity content in creatine monohydrate, preparation method and application thereof | 宁夏享誉生物科技有限公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-112226113-B | Film for cleaning tableware, preparation method thereof and tableware film laminating equipment | 白江龙 | 2024-07-09 | — | — | CN | disclosed |
| CN-115636772-B | Preparation method of high-purity creatine monohydrate | 安徽泰格生物科技有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240148040-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | TARGET CAPITAL 4 LLC | 2024-05-09 | — | — | US | disclosed |
| CN-117756679-A | Method for reducing content of trace and trace impurities in creatine monohydrate | 宁夏大学 | 2024-03-26 | — | — | CN | disclosed |
| WO-2022115353-A1 | METHODS OF REDUCING EXERCISE-INDUCED INJURY OR ENHANCING MUSCLE RECOVERY AFTER EXERCISE | INTRINSIC MEDICINE, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-7968581-B2 | Imidazolidine compounds as androgen receptor modulators | GALAPAGOS NV (BE) | 2011-06-28 | — | — | US | disclosed |
| EP-2319686-A1 | DEOXIDIZING LAMINATE | Mitsubishi Gas Chemical Company, Inc. (JP) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010103539-A2 | SUSTAINED RELEASE ORAL FORMULATION OF VINPOCETINE | PATEL DINESH SHANTILAL (IN) | 2010-09-16 | — | — | WO | disclosed |
| US-20100113547-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AKASHI THERAPEUTICS, INC. | 2010-05-06 | — | — | US | disclosed |
| WO-2010029119-A1 | NOVEL IMIDAZOLIDINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | GALAPAGOS NV (BE) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009120182-A2 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ACTIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090163449-A1 | SULFO-POLYMER POWDER AND SULFO-POLYMER POWDER BLENDS WITH CARRIERS AND/OR ADDITIVES | EASTMAN CHEMICAL COMPANY (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080311613-A1 | ARTIFICIAL SKIN SURFACE FILM LIQUIDS | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2008-12-18 | — | — | US | disclosed |
| US-6617356-B2 | Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements | NATURALLY SCIENTIFIC, INC. | 2003-09-09 | — | — | US | disclosed |
| US-20010006671-A1 | GEL SYSTEM FOR ORAL AND TOPICAL ADMINISTRATION OF WATER INSOLUBLE AND/OR WATER INTOLERANT DRUGS AND SUPPLEMENTS | NATURALLY SCIENTIFIC, INC. | 2001-07-05 | — | — | US | disclosed |